Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hegge KA et al. – Sapropterin offers a promising therapeutic option for select individuals with BH4–responsive PKU, although long–term data are limited evaluating its safety and efficacy in traditional clinical practice settings. When considering sapropterin therapy, clinicians must consider factors such as cost and patient adherence to drug therapy and/or diet.

Related Articles

Alternative Therapies in Phenylketonuria
Topics in Clinical Nutrition, 11/16/09    Relevance Score: 83%%

Evaluation of Somatic Development in Adult Patients with Previously Undiagnosed and/or Untreated Phenylketonuria
Medical Principles and Practice, 12/15/09    Relevance Score: 82%%

Mutational spectrum of Phenylketonuria in the Chinese Han population: A novel insight into the geographic distribution of the common mutations
Pediatric Research, 12/07/09    Relevance Score: 82%%

Normal Fatty Acid Concentrations in Young Children With Phenylketonuria
Topics in Clinical Nutrition, 11/16/09    Relevance Score: 82%%

United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
BioMarin, 11/06/09    Relevance Score: 80%%

Today in Other Drugs...keeping you current

Dienogest: a new therapeutic agent for the treatment of endometriosis *TEST*
Women's Health, 12/17/09

Investigational drugs for allergic rhinitis
Expert Opinion on Investigational Drugs, 12/17/09

Predicting short term response to anti-inflammatory therapy in young children with asthma
Current Medical Research and Opinion, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address